Photo from wikipedia
Adverse drug reaction (ADR) reporting is generally of poor quality, which may delay post‐marketing regulatory actions. Here, we evaluated the quality of ADR reporting at our institution and examined the… Click to show full abstract
Adverse drug reaction (ADR) reporting is generally of poor quality, which may delay post‐marketing regulatory actions. Here, we evaluated the quality of ADR reporting at our institution and examined the roles of clinical pharmacists in this process.
Keywords:
drug reaction;
clinical pharmacists;
adverse drug;
quality
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!